By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    bowl of vegetable salad
    Raw Foods: benefits and harms
    November 9, 2021
    pros and cons of the keto diet
    Read This Before You Follow the Keto Diet
    May 18, 2022
    spinal cord injuries
    4 Potential Causes of Spinal Cord Injuries (and How to Seek Compensation)
    May 25, 2022
    Latest News
    Managing Your Health After a Worksite Accident
    December 8, 2023
    Biohazard Cleanup: The Importance of Proper Disposal and Containment
    December 2, 2023
    Medicare Helps Seniors, and People with Disabilities & ESRD
    November 27, 2023
    The Link Between Allergies and Sinusitis & Strategies for Relief
    November 27, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    medical school
    First U.S. Insurer to Build Medical School
    April 14, 2016
    Big Party Candidates and Globe Don’t Get It on Tech
    October 2, 2014
    How Self-Determination Theory Can Improve Medical Students’ Motivation
    September 28, 2020
    Latest News
    Automation in Pharmacovigilance: A Double-Edged Sword
    November 15, 2023
    What Does Science Say About Modern Health Practices?
    November 12, 2023
    Harnessing the Power of Email Marketing in Healthcare
    October 26, 2023
    10 Proven Strategies to Level Up Your Health Business
    October 25, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
Share
Sign In
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
BusinessFinanceSpecialties

Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials

Deanna Pogorelc
Last updated: 2013/10/24 at 8:00 AM
Deanna Pogorelc
Share
4 Min Read
SHARE

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials.

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials. For startup Alzheon, though, those failures have left behind a trail of valuable clinical and biomarker data that it thinks could lead to hidden treasure.

Alzheon launched today with a plan to scoop up abandoned drug candidates to which it thinks it can apply recent advances in the understanding of Alzheimer’s disease and new diagnostic and prognostic tools to refine the drugs and target them toward more specific groups of patients.

For its first clinical candidate, the Lexington, Massachusetts-based biotech has licensed a prodrug of the small molecule tramiprosate from Bellus Health (formerly Neurochem Inc.) of Quebec, Canada. It was designed to inhibit the formation of amyloid assemblies in the brain that experts have long considered characteristic of the disease.

In the late 2000s, Neurochem took the drug as far as Phase 3 studies involving more than a thousand Alzheimer’s disease patients. It failed to meet the trial’s efficacy endpoints.

But in a retrospective analysis of clinical data, researchers found that the drug seemed to slow atrophy of the hippocampus, a kind of brain damage associated with Alzheimer’s, especially in patients with a gene variation called APOE4.

Alzheon will piggyback on those clues and use a prodrug form of tramiprosate, or an inactive substance that is converted into an active drug inside the body. CEO Dr. Martin Tolar said the prodrug has better properties than its parent drug.

Tolar is a neurologist by training and spent six years in leadership positions at Pfizer before taking on roles at various smaller biotech companies including CoMentis Inc., NormOxys and Knome Inc. Working with him on this new venture is former CoMentis and NormOxys colleague John Hey, a 20-year drug development veteran, and Dr. Mark Versavel, who has led neurology projects at Bayer and Pfizer.

The team will use their combined science and business savvy and the existing clinical data behind ALZ-801 to design a Phase 2 efficacy study around specific subpopulations of Alzheimer’s patients who stand to benefit most from the drug. Tolar said the trial should start next year.

While smaller, more targeted trials should in theory be quicker and more likely to produce positive results than large trials, the trials will still be costly. Tolar declined to disclose details of his company’s initial financing but said his team is working with two private investors with a history success in biopharmaceuticals.

As plans for the trial get underway, Alzheon, which was incorporated in August, is also at work building a pipeline. Tolar said the team is in talks with other companies about in-licensing deals that would bring in other therapeutic approaches that have demonstrated safety and proof-of-concept activity in neurodegenerative disease.

Chief Scientific Officer Hey summed up the company’s long-term strategy in a statement: “Alzheon has unique capabilities to deploy our drug development platform and leverage the clinical knowledgebase from past Alzheimer’s programs to deliver the best of both worlds:  innovative treatments for challenging neurodegenerative diseases and well-designed clinical programs that have a high likelihood of success.”

Follow MedCity News on Facebook and Twitter for more updates.

[Image credit: BigStock Photos]

TAGGED: Alzheimers, Alzheon

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Deanna Pogorelc October 24, 2013 October 24, 2013
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Image It’s a Patient-Payer World
Next Article caregivers Family Caregivers Live Longer Than Non-Caregivers: Mortality Rates 18% Lower

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

Managing Your Health After a Worksite Accident
Managing Your Health After a Worksite Accident
Health December 8, 2023
How to Plan for a Dental Implant Procedure
How to Plan for a Dental Implant Procedure
Dental health December 8, 2023
weight loss
The Key Steps For Affective Weight Loss And Improving Health
Weight Loss Wellness December 6, 2023
Empowering Wellness: HBOT for Home Use Demystified
Empowering Wellness: HBOT for Home Use Demystified
Wellness December 5, 2023

You Might also Like

How to Plan for a Dental Implant Procedure
Dental health

How to Plan for a Dental Implant Procedure

December 8, 2023
Invasive Dentistry
Dental healthSpecialties

Precision And Comfort: The Role Of Lasers In Minimally Invasive Dentistry

December 4, 2023
sublingual immunotherapy
AllergySpecialties

Sublingual Immunotherapy: A Safe and Effective Alternative to Allergy Shots

December 2, 2023
allergies and sinusitis
Health

The Link Between Allergies and Sinusitis & Strategies for Relief

November 27, 2023
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2008-2023 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Lost your password?